Fagron NV (FAGR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fagron NV (FAGR) has a cash flow conversion efficiency ratio of 0.073x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€43.76 Million ≈ $51.16 Million USD) by net assets (€599.55 Million ≈ $700.94 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Fagron NV stock valuation for the company's overall valuation and market capitalisation.
Fagron NV - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Fagron NV's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Fagron NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fagron NV ranked by their cash flow conversion efficiency. Explore cash flow quality index of Fagron NV to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Allient Inc.
NASDAQ:ALNT
|
0.045x |
|
Hangzhou Shunwang Tech
SHE:300113
|
0.044x |
|
Airport City Ltd
TA:ARPT
|
0.013x |
|
PSMC CO. Ltd
KQ:024850
|
-0.032x |
|
Guangdong Guangzhou Daily Media Co Ltd
SHE:002181
|
0.028x |
|
Ningbo PIA Automation Holding Corp. A
SHG:688306
|
N/A |
|
Shinkong Insurance Co Ltd
TW:2850
|
0.144x |
|
Shenzhen Bluetrum Technology Co. Ltd. A
SHG:688332
|
N/A |
Annual Cash Flow Conversion Efficiency for Fagron NV (2004–2025)
The table below shows the annual cash flow conversion efficiency of Fagron NV from 2004 to 2025. View FAGR live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €556.26 Million ≈ $650.32 Million |
€128.28 Million ≈ $149.97 Million |
0.231x | +6.05% |
| 2024-12-31 | €505.36 Million ≈ $590.82 Million |
€109.89 Million ≈ $128.48 Million |
0.217x | -5.30% |
| 2023-12-31 | €467.63 Million ≈ $546.70 Million |
€107.38 Million ≈ $125.54 Million |
0.230x | -14.28% |
| 2022-12-31 | €408.63 Million ≈ $477.73 Million |
€109.46 Million ≈ $127.97 Million |
0.268x | +11.17% |
| 2021-12-31 | €325.47 Million ≈ $380.50 Million |
€78.42 Million ≈ $91.68 Million |
0.241x | -33.17% |
| 2020-12-31 | €257.82 Million ≈ $301.42 Million |
€92.95 Million ≈ $108.67 Million |
0.361x | +15.13% |
| 2019-12-31 | €246.44 Million ≈ $288.12 Million |
€77.17 Million ≈ $90.23 Million |
0.313x | -10.38% |
| 2018-12-31 | €209.72 Million ≈ $245.18 Million |
€73.28 Million ≈ $85.67 Million |
0.349x | -23.32% |
| 2017-12-31 | €184.88 Million ≈ $216.15 Million |
€84.25 Million ≈ $98.49 Million |
0.456x | +3.20% |
| 2016-12-31 | €152.87 Million ≈ $178.73 Million |
€67.50 Million ≈ $78.92 Million |
0.442x | +139.01% |
| 2015-12-31 | €-64.77 Million ≈ $-75.73 Million |
€73.31 Million ≈ $85.71 Million |
-1.132x | -274.67% |
| 2014-12-31 | €156.94 Million ≈ $183.48 Million |
€101.70 Million ≈ $118.89 Million |
0.648x | +59.40% |
| 2013-12-31 | €155.17 Million ≈ $181.41 Million |
€63.08 Million ≈ $73.74 Million |
0.407x | +47.25% |
| 2012-12-31 | €245.38 Million ≈ $286.88 Million |
€67.74 Million ≈ $79.20 Million |
0.276x | -15.64% |
| 2011-12-31 | €220.45 Million ≈ $257.73 Million |
€72.15 Million ≈ $84.35 Million |
0.327x | +61.69% |
| 2010-12-31 | €208.12 Million ≈ $243.32 Million |
€42.13 Million ≈ $49.25 Million |
0.202x | +0.63% |
| 2009-12-31 | €196.35 Million ≈ $229.56 Million |
€39.50 Million ≈ $46.17 Million |
0.201x | +34.53% |
| 2008-12-31 | €185.53 Million ≈ $216.90 Million |
€27.74 Million ≈ $32.43 Million |
0.150x | -1.67% |
| 2007-12-31 | €178.22 Million ≈ $208.36 Million |
€27.10 Million ≈ $31.68 Million |
0.152x | -17.89% |
| 2006-12-31 | €94.88 Million ≈ $110.93 Million |
€17.57 Million ≈ $20.54 Million |
0.185x | -55.57% |
| 2005-12-31 | €82.87 Million ≈ $96.88 Million |
€34.54 Million ≈ $40.38 Million |
0.417x | +372.91% |
| 2004-12-31 | €102.54 Million ≈ $119.88 Million |
€9.04 Million ≈ $10.57 Million |
0.088x | -- |
About Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Com… Read more